Inhibrx Biosciences Inc 뉴스 - INBX | 주식 나스닥 | ADVFN

다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Inhibrx Biosciences Inc (INBX)
Inhibrx Biosciences Inc (INBX) 뉴스

Inhibrx Biosciences Inc (INBX)

12.49

-0.07

(-0.56%)

종가: 25 2월 6:00AM

12.49

0.01

( 0.08% )

시간외 거래: 6:03AM

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi PR Newswire SAN DIEGO, May 24, 2024 SAN DIEGO...

Form 144 - Report of proposed sale of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off PR Newswire SAN DIEGO, May...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

1
2
다음

Monksdream

Monksdream 4 월 전

Monksdream

Monksdream 5 월 전

Monksdream

Monksdream 6 월 전

Monksdream

Monksdream 11 월 전

TrendTrade2016

TrendTrade2016 2 년 전

heres the dolla...boom!!

TrendTrade2016

TrendTrade2016 2 년 전

INBX DOLLA RUMMER IN PROCESS

TrendTrade2016

TrendTrade2016 2 년 전

INBX...PRE MARKET VOL

Jaydixson1

Jaydixson1 2 년 전

Seems to be dropping

make it happen

make it happen 2 년 전

Numbers do not make sense. They need to raise so much to keep the Phases going. So much debt and money burn with worse quarters and barley any revs. Not bashing it's just what it is. 1,000's of percent's negative on profit. Revenue $0.18 Book Value -$0.12. Also imo this volume isn't sustainable 9 times normal as of now

Profitability
Profit Margin 0.00%
Operating Margin -1,448.76%

Management Effectiveness
Return on Assets -37.98%
Return on Equity -562.25%

Income Statement
Revenue 7.03M
Revenue Per Share 0.18
Quarterly Revenue Growth (yoy) -25.50%
Gross Profit -64.21M
EBITDA -100.6M
Net Income Avi to Common -110.75M
Diluted EPS -2.44

Balance Sheet
Total Debt 175.7M
Book Value Per Share -0.13

Cash Flow Statement
Operating Cash Flow -90.16M
Levered Free Cash Flow -46.31M

Inhibrx Biosciences

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관